Combined STAT3 and BCR-ABL1 Inhibition Induces Synthetic Lethality in Therapy-Resistant Chronic Myeloid Leukemia

Mutations in the BCR-ABL1 kinase domain are an established mechanism of tyrosine kinase inhibitor (TKI) resistance in Philadelphia chromosome-positive leukemia, but fail to explain many cases of clinical TKI failure. In contrast, it is largely unknown why some patients fail TKI therapy despite conti...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Leukemia
Main Authors: Eiring, Anna M., Page, Brent D. G., Kraft, Ira L., Mason, Clinton C., Vellore, Nadeem A., Resetca, Diana, Zabriskie, Matthew S., Zhang, Tian Y., Khorashad, Jamshid S., Engar, Alexander J., Reynolds, Kimberly R., Anderson, David J., Senina, Anna, Pomicter, Anthony D., Arpin, Carolynn C., Ahmad, Shazia, Heaton, William L., Tantravahi, Srinivas K., Todic, Aleksandra, Moriggl, Richard, Wilson, Derek J., Baron, Riccardo, O'Hare, Thomas, Gunning, Patrick T., Deininger, Michael W.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4334758/
https://ncbi.nlm.nih.gov/pubmed/25134459
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2014.245
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados